Primary Sclerosing Cholangitis in Children
Key facts
- Who runs it
- Arbor Research Collaborative for Health
- Where
- Atlanta, Aurora, Chicago, Cincinnati, Houston, Indianapolis, Los Angeles, Philadelphia, Pittsburgh, Salt Lake City, and Seattle, United StatesSee the 11 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 30 Dec 2021
- Expected to end
- 31 May 2029
- Type of study
- Observational
- Record updated
- 14 July 2026
Who can take part
- Age
- 2 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Patients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment
- Individuals must meet all of the Inclusion criteria in order to be eligible to participate in the study:
- Aged 2 through 25 years at time of screening
- Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:; Focal structuring of the bile duct(s); Dominant stricture of the common bile duct; Saccular dilatation of bile duct(s); Beaded appearance of bile duct(s); Pruning appearance of the distal bile duct branches; AND/OR
- Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:; Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR; Definitive small duct PSC: Periductal fibrosis/ "onion skinning" around interlobular bile ducts or smaller profiles
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Able to provide informed consent/assent; Participants for the imaging study are eligible if they are:
- Aged 8 through 25 years at the time of screening
- No absolute contraindication to MRI
- No skin condition that could be aggravated by MREL
- Meet all other eligibility criteria of the PSC Observational Study
- For whom none of the exclusion criteria apply
Who cannot take part
- History bone marrow transplantation
- History of biliary tract surgery for cholecystolithiasis prior to cholangiogram/liver biopsy evaluated to determine enrollment
- Concurrent pregnancy at the time of enrollment -
- History of liver transplantation
- History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV/AIDS
- History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)
- History of ischemic cholangitis
- History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy
- History of recurrent pyogenic cholangitis
- History of biliary tract surgery for choledochal cyst
- History of hepatocellular carcinoma, or hepatoblastoma
- History of surgical biliary trauma
- History of congenital cytomegalovirus (CMV) hepatitis
- History of Sickle Cell Disease
- History of cystic fibrosis, biliary atresia, Caroli disease/congenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3/MDR3 disease
- History of cardiac hepatopathy
- History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency
- An individual who meets any of the following criteria at baseline will be excluded from participation in this study
- Diagnosis of systemic lupus erythematosus (SLE)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 25 years old?
Where in United States
Also in 1 other country, 1 site
- Children's Healthcare of AtlantaAtlanta, United StatesContact: Jordyn TurnerTaking people
- Children's Hospital ColoradoAurora, United StatesContact: Cynthia CastanonTaking people
- Ann & Robert H. Lurie Children's HospitalChicago, United StatesContact: Angela AnthonyTaking people
- Cincinnati Children's Hospital MedicalCincinnati, United StatesContact: Erin Chapman, BASTaking people
- Texas Children's Hospital/ Baylor College of MedicineHouston, United StatesContact: Alyia ThomasTaking people
- Riley Hospital for ChildrenIndianapolis, United StatesContact: Melissa Sexton, BBA, CCRPNo longer taking part
- Children's Hospital of Los AngelesLos Angeles, United StatesContact: Sirikorn BoonsawatTaking people
- The Children's Hospital Of PhiladelphiaPhiladelphia, United StatesContact: Caitlin Griffiths, MSTaking people
- UPMC Children's Hospital of PittsburghPittsburgh, United StatesContact: Melissa Sexton, BBA, CCRPNo longer taking part
- The University of UtahSalt Lake City, United StatesContact: Ann Rutherford, BS, CCRPTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Melissa YoungTaking people
About the trial
What the trial wants to find out
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.
Read full original descriptionShow less
The purposes of this study are to:
* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly. * Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning * Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children
- Fit questions
- Built from NCT04181138, who can take part
- Record updated
- 14 July 2026